China's NMPA accepts Junshi Biosciences' sNDA for toripalimab+bevacizumab combo in first-line HCC treatment.

Shanghai Junshi Biosciences announces that China's National Medical Products Administration (NMPA) accepted its supplemental new drug application (sNDA) for toripalimab (TUOYI®) combined with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Junshi Biosciences is a leading biopharmaceutical company dedicated to novel therapy development.